NEW YORK, Jan. 3 (UPI) -- Wyeth and Trubion Pharmaceuticals have reportedly entered a pact to develop antibody drugs.
A report in Tuesday's Wall Street Journal said the development deal calls for Wyeth, based in Madison, N.J., to make an upfront payment to privately held Trubion of $40 million.
Advertisement
The report also said the pact could be worth as much as $800 million, provided that certain milestones are met.
In addition, the Journal report said that Wyeth agreed to take an equity stake in Seattle-based Trubion if the company goes public.